Baton Rouge, LA, United States of America

Nikhil V Dhurandhar

This inventor holds 14 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Obetech, LLC, Louisiana State University and Agricultural & Mechanical College, Board of Sup. of Lsu and Agr. & Mechanical College. Active years: 2000-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nikhil V Dhurandhar. Retrieved from https://idiyas.com/inventor/nikhil-v-dhurandhar

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 3)

% Patents Active = 85.7

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 1.9

ph-index = 3

Forward Citations = 39(Granted Patents)

Location History:

Madison, WI (US) (2000 - 2003)
Rochester Hills, MI (US) (2007 - 2011)
Baton Rogue, LA (US) (2007 - 2015)
Baton Rouge, LA (US) (2011 - 2018)

Company Filing History:

Louisiana State University and Agricultural & Mechanical College

patents

1 out of 1

Board of Sup. of Lsu and Agr. & Mechanical College

patent

4. 1 out of 603

Wayne State University

patents

where one patent can have more than one assignee

Years Active: 2000-2018

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10047107 - Small molecule analogs of E4orf1 (2018-08-14),

2. 9714259 - Compositions and methods for improving glucose uptake (2017-07-25),

3. 9469659 - Compositions and methods for improving glucose uptake (2016-10-18),

4. 9433659 - Enhanced glycemic control using Ad36E4orf1 and AKT1 inhibitor (2016-09-06),

5. 9346835 - Compositions and methods for improving glucose uptake (2016-05-24),

6. 8951980 - Adenovirus Ad36 E4 orf1 protein for prevention and treatment of non-alcoholic fatty liver disease (2015-02-10),

7. 8008436 - Adenovirus 36 E4 orf 1 gene and protein and their uses (2011-08-30),

8. RE42129 - Viral obesity methods and compositions (2011-02-07),

9. RE40832 - Viral obesity methods and compositions (2009-07-06),

10. 7507418 - Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes (2009-03-24),

11. RE39914 - Viral obesity methods and compositions (2007-11-05),

12. RE39544 - Viral obesity methods and compositions (2007-04-02),

13. 6664050 - Viral obesity methods and compositions (2003-12-16),

14. 6127113 - Viral obesity methods and compositions (2000-10-03),

Title: Nikhil V Dhurandhar: Innovating Glucose Uptake Solutions

Introduction

Nikhil V Dhurandhar is a distinguished inventor based in Baton Rouge, LA (US), renowned for his contributions to the field of biochemistry and pharmacology. With 14 patents to his name, his work focuses on innovative compounds that enhance glucose uptake while minimizing adipogenesis, addressing significant metabolic health challenges.

Latest Patents

Among his latest patents, Dhurandhar has developed small molecule analogs of E4orf1, which include amino nitrile compounds. These novel compounds are designed to increase glucose uptake by cells without significantly promoting adipogenesis. Another notable patent features compositions and methods for improving glucose uptake, defined by a general Formula II, including pharmaceutically acceptable salts and solvates. This complex structure allows for various substitutions that promote effective glucose metabolism, further advancing therapeutic options for diabetes management.

Career Highlights

Dhurandhar's career includes significant contributions while working at Obetech, LLC, and Louisiana State University and Agricultural & Mechanical College. His research and innovations have greatly impacted the understanding of glucose metabolism, aligning with global health priorities.

Collaborations

Throughout his career, Dhurandhar has collaborated with notable colleagues such as Richard L Atkinson and Bhaskar C Das. These collaborations have fostered a dynamic exchange of ideas and have led to advancements in the development of his patented compounds.

Conclusion

Nikhil V Dhurandhar's innovative work exemplifies the intersection of science and practical solutions for health issues related to glucose metabolism. His patents represent a significant contribution to the field, potentially offering new avenues for treating metabolic disorders. As he continues to push the boundaries of research, his impact on the scientific community and public health is poised to grow.

Profile summary based on public USPTO records.